Indications and recent evidence for apheresis in children and adults with kidney diseases: a comprehensive review
Bibliographic record
Abstract
Introduction: Plasmapheresis has been a therapeutic option in kidney diseases to eliminate disease-causing autoantibodies, circulating factors, and abnormal components involved in complement pathways. We aim to systematically review the effectiveness and adverse events associated with plasmapheresis and related apheresis therapies in treating kidney diseases in paediatric and adult populations. Methods: We searched databases including EMBASE, CINAHL, PubMed, and Cochrane Central for studies from 2010 to October 2023. The search terms included terms related to glomerulonephritis treated with plasmapheresis. Outcomes included the patient's length of hospital stay, mortality, development of kidney failure, associated comorbidities, and adverse events. Risk of bias was assessed using the Newcastle-Ottawa Scale, and meta-analyses were performed to calculate pooled adverse event rates. Results: A total of 33 studies with 1363 participants were included. The pooled proportion of kidney failure was 26.36% (95% CI 17.38%-36.47%), and the rate of dialysis requirement was 30.43% (95% CI 14.80%-48.82%). The mortality rate was 10.86% (95% CI 9.12%-12.81%). Adverse events were reported in 31.03% (95% CI 12.78%-53.05%) of cases. Heterogeneity was significant for most outcomes. We also performed a literature review due to a lack of adequate studies regarding the use of plasmapheresis in lupus nephritis, multiple myeloma, and atypical haemolytic uremic syndrome, as well as the use of low-density lipoprotein apheresis in kidney diseases. Discussion: Plasmapheresis has demonstrated remission in patients with kidney diseases, particularly in those with ANCA-associated vasculitis and FSGS. Based on the results of our systematic review, we discuss the use of plasmapheresis for treating glomerular diseases, atypical haemolytic uremic syndrome, other kidney diseases, and the usage of low-density lipoprotein apheresis. Further research is needed to improve patient outcomes and reduce complications, especially in paediatric populations.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.011 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.005 | 0.006 |
| Bibliometrics | 0.009 | 0.009 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.002 | 0.002 |
| Open science | 0.002 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.006 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".